Nishant Agrawal to Oropharyngeal Neoplasms
This is a "connection" page, showing publications Nishant Agrawal has written about Oropharyngeal Neoplasms.
Connection Strength
4.089
-
Personalizing Surveillance in Head and Neck Cancer. Am Soc Clin Oncol Educ Book. 2023 01; 43:e389718.
Score: 0.744
-
Novel Strategies to Effectively De-escalate Curative-Intent Therapy for Patients With HPV-Associated Oropharyngeal Cancer: Current and Future Directions. Am Soc Clin Oncol Educ Book. 2020 Mar; 40:1-13.
Score: 0.611
-
Retropharyngeal lymph node involvement in human papillomavirus-associated oropharyngeal squamous cell carcinoma. Laryngoscope. 2015 Nov; 125(11):2503-8.
Score: 0.445
-
Oral cavity and oropharyngeal squamous cell carcinoma genomics. Otolaryngol Clin North Am. 2013 Aug; 46(4):545-66.
Score: 0.384
-
Retrospective review of positron emission tomography with contrast-enhanced computed tomography in the posttreatment setting in human papillomavirus-associated oropharyngeal carcinoma. Arch Otolaryngol Head Neck Surg. 2012 Nov; 138(11):1040-6.
Score: 0.368
-
Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-Adaptive Therapy for HPV+ Oropharyngeal Cancer: OPTIMA II Phase 2 Open-Label Nonrandomized Controlled Trial. JAMA Oncol. 2024 Jul 01; 10(7):923-931.
Score: 0.206
-
Development and Validation of a Decision Analytical Model for Posttreatment Surveillance for Patients With Oropharyngeal Carcinoma. JAMA Netw Open. 2022 04 01; 5(4):e227240.
Score: 0.177
-
Prospective study evaluating dynamic changes of cell-free HPV DNA in locoregional viral-associated oropharyngeal cancer treated with induction chemotherapy and response-adaptive treatment. BMC Cancer. 2022 Jan 03; 22(1):17.
Score: 0.174
-
Risk and response adapted de-intensified treatment for HPV-associated oropharyngeal cancer: Optima paradigm expanded experience. Oral Oncol. 2021 11; 122:105566.
Score: 0.171
-
Dose and Volume De-Escalation for Human Papillomavirus-Positive Oropharyngeal Cancer is Associated with Favorable Posttreatment Functional Outcomes. Int J Radiat Oncol Biol Phys. 2020 07 15; 107(4):662-671.
Score: 0.154
-
E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group. J Clin Oncol. 2017 Feb 10; 35(5):490-497.
Score: 0.123
-
Serum Antibodies to HPV16 Early Proteins Warrant Investigation as Potential Biomarkers for Risk Stratification and Recurrence of HPV-Associated Oropharyngeal Cancer. Cancer Prev Res (Phila). 2016 Feb; 9(2):135-41.
Score: 0.114
-
Disease-free survival after salvage therapy for recurrent oropharyngeal squamous cell carcinoma. Head Neck. 2016 04; 38 Suppl 1:E1501-9.
Score: 0.113
-
The Impact of Tonsillectomy upon the Risk of Oropharyngeal Carcinoma Diagnosis and Prognosis in the Danish Cancer Registry. Cancer Prev Res (Phila). 2015 Jul; 8(7):583-9.
Score: 0.109
-
Surgical salvage improves overall survival for patients with HPV-positive and HPV-negative recurrent locoregional and distant metastatic oropharyngeal cancer. Cancer. 2015 Jun 15; 121(12):1977-84.
Score: 0.108
-
Volumetric change of human papillomavirus-related neck lymph nodes before, during, and shortly after intensity-modulated radiation therapy. Head Neck. 2012 Nov; 34(11):1640-7.
Score: 0.087